全文获取类型
收费全文 | 28776篇 |
免费 | 2020篇 |
国内免费 | 1504篇 |
专业分类
耳鼻咽喉 | 125篇 |
儿科学 | 411篇 |
妇产科学 | 435篇 |
基础医学 | 5228篇 |
口腔科学 | 707篇 |
临床医学 | 2213篇 |
内科学 | 3941篇 |
皮肤病学 | 337篇 |
神经病学 | 2049篇 |
特种医学 | 783篇 |
外国民族医学 | 9篇 |
外科学 | 5267篇 |
综合类 | 4122篇 |
现状与发展 | 4篇 |
预防医学 | 1222篇 |
眼科学 | 456篇 |
药学 | 2825篇 |
7篇 | |
中国医学 | 318篇 |
肿瘤学 | 1841篇 |
出版年
2024年 | 75篇 |
2023年 | 355篇 |
2022年 | 775篇 |
2021年 | 1009篇 |
2020年 | 765篇 |
2019年 | 652篇 |
2018年 | 701篇 |
2017年 | 766篇 |
2016年 | 855篇 |
2015年 | 924篇 |
2014年 | 1633篇 |
2013年 | 1976篇 |
2012年 | 1579篇 |
2011年 | 1784篇 |
2010年 | 1497篇 |
2009年 | 1615篇 |
2008年 | 1571篇 |
2007年 | 1608篇 |
2006年 | 1533篇 |
2005年 | 1438篇 |
2004年 | 1264篇 |
2003年 | 1098篇 |
2002年 | 862篇 |
2001年 | 798篇 |
2000年 | 599篇 |
1999年 | 558篇 |
1998年 | 450篇 |
1997年 | 429篇 |
1996年 | 377篇 |
1995年 | 354篇 |
1994年 | 295篇 |
1993年 | 228篇 |
1992年 | 221篇 |
1991年 | 195篇 |
1990年 | 180篇 |
1989年 | 162篇 |
1988年 | 122篇 |
1987年 | 107篇 |
1986年 | 77篇 |
1985年 | 144篇 |
1984年 | 130篇 |
1983年 | 84篇 |
1982年 | 87篇 |
1981年 | 86篇 |
1980年 | 67篇 |
1979年 | 60篇 |
1978年 | 45篇 |
1977年 | 42篇 |
1976年 | 21篇 |
1975年 | 13篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
《Revista brasileira de otorrinolaringologia (English ed.)》2022,88(5):803-811
ObjectivesTo review the evidence pertaining to the association between cow’s milk protein allergy and recurrent acute otitis media and otitis media with effusion.MethodsThe CENTRAL, Web of Science, EMBASE, MEDLINE, LILACS databases, and gray literature were searched.ResultsFour studies were included, identifying the prevalence rates: 0.2% of delayed speech due to chronic otitis media with effusion in 382 children with cow’s milk protein allergy, 10.7% of cow’s milk protein allergy in 242 children who underwent ENT procedures, 40% of cow’s milk protein allergy in 25 children with recurrent otitis media with effusion and higher tendency to otitis media in children with cow’s milk protein allergy of 186 children (1.5 + 0.6 vs. 0.4 + 0.1; p < 0.1).ConclusionConsidering the characteristics and methodological variations of the identified studies, it is not possible to state that there is reliable evidence of an association between cow’s milk protein allergy and otitis media. 相似文献
12.
目的采用图像融合技术获得T2WI与T2WI-FS的融合图像,评估其在肛瘘及肛周结构显示中的优势。
方法2016年6月至2018年6月,前瞻性选择中山大学附属第一医院29例肛瘘患者进行肛管磁共振(MR)检查,采用图像融合技术获取T2WI与T2WI-FS的融合图像T2WI-Fusion,利用Fisher score算法计算瘘管及肛门括约肌的组织间分辨力Fisher值、脂肪与肛门括约肌间的Fisher值,评估融合图像中瘘管及肛周结构的显示情况。采用改进的双刺激连续质量量表(DSCQS)对T2WI-FS、T2WI、增强3D-VIBE和T2WI-Fusion序列图像进行主观图像质量评价。
结果29例患者均成功获得T2WI与T2WI-FS的融合图像T2WI-Fusion。T2WI-Fusion、T2WI瘘管与括约肌间Fisher均值分别为6.46、3.31,T2WI-Fusion图像对瘘管的显示优于T2WI序列图像(P<0.001)。T2WI-Fusion、T2WI-FS脂肪与括约肌间Fisher均值分别为10.61、2.45,T2WI-Fusion图像对括约肌的显示优于T2WI-FS序列图像(P<0.001)。T2WI-Fusion对瘘管与括约肌的图像质量评价总评分均高于T2WI-FS、T2WI、增强3D-VIBE序列(P<0.001)。
结论MRI图像融合技术同时具备T2WI及T2WI-FS的优势,无需增加扫描序列及扫描时间,且操作简单,花费时间短,显著提高病变及肛周解剖结构的对比度和图像质量。 相似文献
13.
O. Morris M. Fairclough J. Grigg C. Prenant A. McMahon 《Journal of labelled compounds & radiopharmaceuticals》2019,62(1):4-23
Affinity peptide and protein‐ (APP) based radiotracers are an increasingly popular class of radiotracer in positron emission tomography (PET), which was once dominated by the use of small molecule radiotracers. Radiolabelled monoclonal antibodies (mAbs) are important examples of APPs, yet a preference for smaller APPs, which exhibit fast pharmacokinetics and permit rapid PET aided diagnosis, has become apparent. 18F exhibits favourable physical characteristics for APP radiolabelling and has been described as an ideal PET radionuclide. Notwithstanding, 18F radiolabelling of APP is challenging, and this is echoed in the literature where a number of diverse approaches have been adopted. This review seeks to assess and compare the approaches taken to 18F APP radiolabelling with the intention of highlighting trends within this expanding field. Generic themes have emerged in the literature, namely the use of mild radiolabelling conditions, a preference of site‐specific methodologies with an impetus for short, automated procedures which produce high‐yielding [18F]APPs. 相似文献
14.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献15.
目的:通过检测人绒癌细胞株Be Wo合体化过程中增殖细胞核抗原(proliferating cell nuclear antigen,PCNA)、生存素(Survivin)蛋白表达的变化,探讨滋养细胞合体化后增殖性的变化,为恶性滋养细胞肿瘤,尤其是耐药恶性滋养细胞肿瘤的临床治疗提供新的思路和方法。方法:利用毛喉素(forskolin)诱导Be Wo细胞株融合;应用逆转录聚合酶链反应(RT-PCR)检测促融素(Syncytin)在forskolin作用不同时间的Be Wo细胞株中的表达;应用蛋白质印迹(Western blotting)检测PCNA、Survivin蛋白在forskolin作用不同时间的Be Wo细胞株中的表达;应用噻唑蓝比色分析实验(MTT)法检测forskolin作用不同时间的绒癌细胞株Be Wo的增殖能力。结果:1forskolin作用后的Be Wo细胞株Syncytin基因的表达增强,且随着forskolin作用时间的延长,Syncytin的表达更强,于48 h达到高峰。2forskolin作用后的Be Wo细胞株PCNA、Survivin蛋白的表达降低。3forskolin作用后的Be Wo细胞株的增殖能力下降,且不同作用时间的差异有统计学意义;forskolin作用的时间越长,Be Wo细胞株增殖能力下降越明显。结论:人绒癌细胞株Be Wo合体化后PCNA、Survivin蛋白的表达降低,说明人绒癌细胞株Be Wo合体化后增殖性降低,推测诱导滋养细胞合体化可能对临床治疗恶性滋养细胞肿瘤具有一定作用。 相似文献
16.
《Drug metabolism and pharmacokinetics》2019,34(1):87-94
The purpose of this study was to elucidate the involvement of Mate1 in the tubular secretion of trimethoprim and saturation of Mate1-mediated efflux to address the mechanisms underlying the pharmacokinetic drug interactions with trimethoprim. Trimethoprim is a more potent inhibitor of MATE2-K than MATE1 with Ki values (μM) of 0.030–0.28 and 2.4–5.9, respectively. Trimethoprim is a substrate of human MATE1 and MATE2-K with Km values of 2.3 ± 0.9 and 0.018 ± 0.004 μM, and mouse Mate1, but not human OCT2, mouse Oct1 and Oct2. Pyrimethamine significantly reduced the renal clearance (CLR) of trimethoprim (mL/min/kg) from 40.0 ± 5.1 to 20.1 ± 3.7 (p < 0.05). Trimethoprim was given to mice at three infusion rates (150, 500, and 1500 nmol/min/kg). Together with an increase in the plasma concentrations of trimethoprim, the CLR (mL/min/kg) of trimethoprim decreased to 25.9 ± 3.2, 13.5 ± 5.7, and 8.92 ± 1.50 at the respective rates. Trimethoprim decreased the CLR of rhodamine 123 in an infusion rate-dependent manner: 11.5 ± 1.3 (control), 5.17 ± 1.55, 1.31 ± 0.50, and 0.532 ± 0.180. These results suggest that Mate1 mediates the tubular secretion of trimethoprim, and at therapeutic doses, MATEs-mediated efflux can be saturated, and thereby, cause drug interactions with other MATE substrates. 相似文献
17.
18.
《Journal of Clinical Orthopaedics and Trauma》2020,11(2):184-190
ObjectiveProvide an update of the management options for early onset scoliosis patients, including general assessment, conservative and surgical options.MethodsWe included the updated information about the assessment and management options of Early Onset Scoliosis, taking into consideration the non-fusion methods, including the burden on the patient and their family.ResultsWith the heterogeneity of this population, it is difficult to get a consensus about a unified protocol for management. Accordingly, the surgeon dealing with these cases needs to be aware of the broad range of surgical and non-surgical methods when treating these patients.ConclusionThe main aim of early onset scoliosis treatment is to gain a flexible spine associated with normal lung development and thoracic growth. Management needs to be individualized between the surgeon and patient in relation to the etiology and patient conditions. 相似文献
19.
20.